DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Ivosidenib |
DM8S6T7
|
Moderate |
Increased metabolism of Esterified estrogens caused by Ivosidenib mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[5] |
Arn-509 |
DMT81LZ
|
Moderate |
Increased metabolism of Esterified estrogens caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[5] |
Pexidartinib |
DMS2J0Z
|
Moderate |
Increased metabolism of Esterified estrogens caused by Pexidartinib mediated induction of CYP450 enzyme. |
Bone/articular cartilage neoplasm [2F7B]
|
[5] |
MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Esterified estrogens caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[6] |
Eslicarbazepine |
DMZREFQ
|
Moderate |
Increased metabolism of Esterified estrogens caused by Eslicarbazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[5] |
Tazemetostat |
DMWP1BH
|
Moderate |
Increased metabolism of Esterified estrogens caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[7] |
Berotralstat |
DMWA2DZ
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[8] |
Brigatinib |
DM7W94S
|
Moderate |
Increased metabolism of Esterified estrogens caused by Brigatinib mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[9] |
PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Esterified estrogens caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[5] |
Selpercatinib |
DMZR15V
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[10] |
IPI-145 |
DMWA24P
|
Moderate |
Decreased metabolism of Esterified estrogens caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[11] |
Fedratinib |
DM4ZBK6
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[12] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[13] |
Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[14] |
Larotrectinib |
DM26CQR
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Larotrectinib mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[6] |
Fostamatinib |
DM6AUHV
|
Moderate |
Decreased metabolism of Esterified estrogens caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[15] |
----------- |
|
|
|
|
|